Revvity (RVTY) Expected to Announce Quarterly Earnings on Monday

Revvity (NYSE:RVTY) is projected to release its Q4 2025 results before the market opens on Monday, February 2nd. Analysts expect the company to announce earnings of $1.55 per share and revenue of $759.8050 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, February 2, 2026 at 8:00 AM ET.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Monday, October 27th. The company reported $1.18 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.04. The company had revenue of $698.95 million for the quarter, compared to analysts’ expectations of $699.75 million. Revvity had a return on equity of 7.52% and a net margin of 8.44%.The firm’s quarterly revenue was up 2.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.28 earnings per share. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Revvity Stock Down 0.9%

NYSE RVTY opened at $116.64 on Monday. The stock has a market cap of $13.22 billion, a PE ratio of 58.61, a P/E/G ratio of 3.56 and a beta of 1.05. The business has a 50 day moving average price of $102.18 and a two-hundred day moving average price of $94.99. Revvity has a fifty-two week low of $81.36 and a fifty-two week high of $128.29. The company has a quick ratio of 1.44, a current ratio of 1.75 and a debt-to-equity ratio of 0.36.

Revvity declared that its Board of Directors has approved a share repurchase program on Monday, October 27th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 8.7% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

RVTY has been the subject of a number of analyst reports. Guggenheim started coverage on Revvity in a report on Wednesday, October 15th. They issued a “neutral” rating for the company. The Goldman Sachs Group began coverage on shares of Revvity in a research report on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 target price for the company. Robert W. Baird increased their target price on Revvity from $122.00 to $123.00 and gave the stock an “outperform” rating in a report on Tuesday, October 28th. Bank of America cut Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price objective on the stock. in a research note on Monday, December 15th. Finally, Wells Fargo & Company boosted their target price on shares of Revvity from $102.00 to $107.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $113.91.

Institutional Investors Weigh In On Revvity

A number of hedge funds have recently added to or reduced their stakes in RVTY. CIBC Bancorp USA Inc. bought a new position in shares of Revvity during the third quarter worth about $1,409,000. Danske Bank A S acquired a new position in shares of Revvity during the third quarter worth approximately $3,430,000. Dark Forest Capital Management LP acquired a new stake in Revvity in the 3rd quarter valued at approximately $877,000. XTX Topco Ltd bought a new position in shares of Revvity in the third quarter worth $1,318,000. Finally, Verition Fund Management LLC raised its stake in shares of Revvity by 38.1% during the third quarter. Verition Fund Management LLC now owns 56,532 shares of the company’s stock valued at $4,955,000 after purchasing an additional 15,608 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.